Obesity Surgery

, Volume 28, Issue 8, pp 2487–2493 | Cite as

A Screening Study of Potential Carcinogen Biomarkers After Surgical Treatment of Obesity

  • Luciana Teixeira de Siqueira
  • Marcela Silvestre Outtes Wanderley
  • Roberto Afonso da Silva
  • Adriana da Silva Andrade Pereira
  • José Luiz de Lima Filho
  • Álvaro Antônio Bandeira Ferraz
Original Contributions



Obesity has been associated with the development of various types of cancer. Biomarker studies may provide molecular level knowledge of the factors involved in this association, improving clinical practice through new methods of prevention and treatment.


The present study aimed to analyze proteins found in the plasma of obese patients prior to and 6 months after bariatric surgery, using body mass index (BMI) and percentage total weight loss (%TWL) to evaluate, in a prospective manner, the effects of weight loss on the regulation of proteins related to the appearance of tumors.

Material and Methods

This was a cohort study designed to compare parameters before and after intervention. A total of 40 patients were divided into two groups: control (n = 10) and obese (n = 30). The latter group was stratified according to surgical technique used (Roux-en-Y gastric bypass (RYGB) n = 11 and sleeve gastrectomy (SG) n = 19) to remove confounding variables. Blood samples were collected for plasma protein studies using two-dimensional electrophoresis.


Six proteins related to carcinogenesis were hyperexpressed in the obese patients but were absent in the control group and following surgery. These proteins were the beta-receptor of derived growth factor platelet, the receptor of apolipoprotein B, thrombospondin-2, the low-density lipoprotein receptor, transthyretin, and podoplanin.


The current preliminary study thus identified potentially carcinogenic proteins in obese patients. Surgical weight loss resulted in the not detection of these proteins.


Obesity Cancer Biomarkers Proteomics Two-dimensional electrophoresis Bariatric surgery 



The authors thank Dr. Djalma A. de Melo who participated in the statistical analysis of this work.

Author Contribution

Luciana Teixeira de Siqueira is the principal researcher responsible for patients study at the Hospital das Clinicas of Federal University of Pernambuco. Marcela Silvestre Outtes Wanderley is responsible for the proteomic study. Roberto Afonso da Silva is responsible for the evaluation of potential biomarkers. Adriana da Silva Andrade Pereira is responsible for the two-dimensional electrophoresis.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

Ethical Approval

All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    O'Rourke RW. Obesity and cancer: at the crossroads of cellular metabolism and proliferation. Surg Obes Relat Dis. 2014;10:1208–19.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–91.CrossRefPubMedGoogle Scholar
  3. 3.
    Kaidar-Person O, Bar-Sela G, Person B. The two major epidemics of the twenty-first century: obesity and cancer. Obes Surg. 2011;21:1792–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Casagrande DS, Rosa DD, Umpierre D, et al. Incidence of cancer following bariatric surgery: systematic review and meta-analysis. Obes Surg. 2014;24:1499–509.CrossRefPubMedGoogle Scholar
  5. 5.
    Vongsuvanh R, George J, Qiao L, et al. Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Lett. 2013;330:1–10.CrossRefPubMedGoogle Scholar
  6. 6.
    Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010;61:301–16.CrossRefPubMedGoogle Scholar
  7. 7.
    Louie SM, Roberts LS, Nomura DK. Mechanisms linking obesity and cancer. Biochim Biophys Acta. 2013;1831:1499–508.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cottam D, Fisher B, Ziemba A, et al. Tumor growth factor expression in obesity and changes in expression with weight loss: another cause of increased virulence and incidence of cancer in obesity. Surg Obes Relat Dis. 2010;6:538–41.CrossRefPubMedGoogle Scholar
  9. 9.
    Moulin CM, Rizzo LV, Halpern A. Effect of surgery-induced weight loss on immune function. Expert Rev Gastroenterol Hepatol. 2008;2:617–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Sjöström L, Gummesson A, Sjöström CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10:653–62.CrossRefPubMedGoogle Scholar
  11. 11.
    Ostlund MP, Lu Y, Lagergren J. Risk of obesity-related cancer after obesity surgery in a population-based cohort study. Ann Surg. 2010;252(6):972–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Modesitt SC, Hallowell PT, Slack-Davis JK, et al. Women at extreme risk for obesity-related carcinogenesis: baseline endometrial pathology and impact of bariatric surgery on weight, metabolic profiles and quality of life. Gynecol Oncol. 2015;138:238–45.CrossRefPubMedGoogle Scholar
  13. 13.
    Madura 2nd JA, Dibaise JK. Quick fix or long-term cure? Pros and cons of bariatric surgery. F1000 Med Rep. 2012;4:19.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Roa PE, Kaidar-Person O, Pinto D, et al. Laparoscopic sleeve gastrectomy as treatment for morbid obesity: technique and short-term outcome. Obes Surg. 2006;16:1323–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Teucher B, Rohrmann S, Kaaks R. Obesity: focus on all-cause mortality and cancer. Maturitas. 2010;65:112–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Adams TD, Hunt SC. Cancer and obesity: effect of bariatric surgery. World J Surg. 2009;33:2028–33.CrossRefPubMedGoogle Scholar
  17. 17.
    Angrisani L1, Santonicola A, Iovino P, et al. Bariatric surgery worldwide 2013. Obes Surg. 2015;25:1822–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Li JF, Lai DD, Ni B, et al. Comparison of laparoscopic Roux-en-Y gastric bypass with laparoscopic sleeve gastrectomy for morbid obesity or type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Can J Surg. 2013;56:158–64.CrossRefGoogle Scholar
  19. 19.
    Benaiges D, Flores Le-Roux JA, Pedro-Botet J, et al. Sleeve gastrectomy and Roux-en-Y gastric bypass are equally effective in correcting insulin resistance. Int J Surg. 2013;11:309–13.CrossRefPubMedGoogle Scholar
  20. 20.
    Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.CrossRefPubMedGoogle Scholar
  21. 21.
    Ferraz EM, Arruda PCL, Bacelar TS, et al. Tratamento cirúrgico da obesidade mórbida. Rev Col Bras Cir. 2003;30:98–105.CrossRefGoogle Scholar
  22. 22.
    Ashrafian H, Ahmed K, Rowland SP, et al. Metabolic surgery and cancer: protective effects of bariatric procedures. Cancer. 2011 May 1;117(9):1788–99.CrossRefPubMedGoogle Scholar
  23. 23.
    Oberbach A, von Bergen M, Blüher S, et al. Combined serum proteomic and metabonomic profiling after laparoscopic sleeve gastrectomy in children and adolescents. J Laparoendosc Adv Surg Tech A. 2012;22:184–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Oberbach A, Blüher M, Wirth H, et al. Combined proteomic and metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. J Proteome Res. 2011;10:4769–88.CrossRefPubMedGoogle Scholar
  25. 25.
    Dalmas E, Rouault C, Abdennour M, et al. Variations in circulating inflammatory factors are related to changes in calorie and carbohydrate intakes early in the course of surgery-induced weight reduction. Am J Clin Nutr. 2011;94:450–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Onoyama M, Kitadai Y, Tanaka Y, et al. Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer. Neoplasia. 2013;15:1391–9.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kitadai Y. Cancer-stromal cell interaction and tumor angiogenesis in gastric cancer. Cancer Microenviron. 2010;3:109–16.CrossRefPubMedGoogle Scholar
  28. 28.
    Kitamoto S, Yokoyama S, Higashi M, et al. MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors. Oncogene. 2013;32:4614–21.CrossRefPubMedGoogle Scholar
  29. 29.
    Schito L, Rey S, Tafani M, et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci U S A. 2012;109:2707–16.CrossRefGoogle Scholar
  30. 30.
    Nair DG, Miller KG, Lourenssen SR, et al. Inflammatory cytokines promote growth of intestinal smooth muscle cells by induced expression of PDGF-Rβ. J. Cell Mol Med. 2014 Jan 13;Google Scholar
  31. 31.
    Seki N, Toh U, Kawaguchi K, et al. Tricin inhibits proliferation of human hepatic stellate cells in vitro by blocking tyrosine phosphorylation of PDGF receptor and its signaling pathways. J Cell Biochem 2012;113:2346–2355.Google Scholar
  32. 32.
    Fraipont F, Nicholson AC, Feige JJ, et al. Thrombospondins and tumor angiogenesis. Trends Mol Med. 2001;7:401–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Vallbo C, Damber JE. Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model. Acta Oncol. 2005;44:293–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Bard MP, Hegmans JP, Hemmes A, et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol. 2004;31:114–21.CrossRefPubMedGoogle Scholar
  35. 35.
    Kawakami T, Tokunaga T, Hatanaka H, et al. Interleukin 10 expression is correlated with thrombospondin expression and decreased vascular involvement in colon cancer. Int J Oncol. 2001;18:487–91.PubMedGoogle Scholar
  36. 36.
    Liu X, Wang Y, Qu H, et al. Associations of polymorphisms of rs693 and rs1042031 in apolipoprotein B gene with risk of breast cancer in Chinese. Jpn J Clin Oncol. 2013;43:362–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Llanos AA, Makambi KH, Tucker CA, et al. Cholesterol, lipoproteins, and breast cancer risk in African American women. Ethn Dis. 2012;22:281–7.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Liu J, Xu A, Lam KS, et al. Cholesterol-induced mammary tumorigenesis is enhanced by adiponectin deficiency: role of LDL receptor upregulation. Oncotarget. 2013;4:1804–18.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Shen GM, Zhao YZ, Chen MT, et al. Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia. Biochem J. 2012;441:675–83.CrossRefPubMedGoogle Scholar
  40. 40.
    Farias-Eisner G, Su F, Robbins T, et al. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. Am J Obstet Gynecol. 2010;202:1–5.CrossRefGoogle Scholar
  41. 41.
    Nosov V, Su F, Amneus M, et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol. 2009;200:1–5.CrossRefGoogle Scholar
  42. 42.
    Chen J1, Chen LJ, Xia YL, et al. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol. 2013;139:1117–27.CrossRefPubMedGoogle Scholar
  43. 43.
    Shindo K, Aishima S, Ohuchida K, et al. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol Cancer. 2013;12:168.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Luciana Teixeira de Siqueira
    • 1
    • 2
  • Marcela Silvestre Outtes Wanderley
    • 3
    • 4
  • Roberto Afonso da Silva
    • 4
  • Adriana da Silva Andrade Pereira
    • 4
  • José Luiz de Lima Filho
    • 5
    • 4
  • Álvaro Antônio Bandeira Ferraz
    • 1
  1. 1.Department of Surgery, Hospital das ClinicasFederal University of PernambucoRecifeBrazil
  2. 2.RecifeBrazil
  3. 3.University of PernambucoRecifeBrazil
  4. 4.Keizo-Asami Immunopathology LaboratoryRecifeBrazil
  5. 5.Federal University of PernambucoRecifeBrazil

Personalised recommendations